Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG interleukin-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection [Estudio de fase 2a/b, aleatorizado y controlado, de la eficacia y la seguridad de PEG-rIL-29 administrado en combinacion con ribavirina a sujetos con infeccion cronica por el virus de la hepatitis C no tratada previamente].

Trial Profile

Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG interleukin-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection [Estudio de fase 2a/b, aleatorizado y controlado, de la eficacia y la seguridad de PEG-rIL-29 administrado en combinacion con ribavirina a sujetos con infeccion cronica por el virus de la hepatitis C no tratada previamente].

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Peginterferon lambda-1a (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMERGE
  • Sponsors ZymoGenetics
  • Most Recent Events

    • 13 Nov 2012 Primary endpoint 'Early-virological-response-rate' has been met.
    • 12 Nov 2012 Results from genotype 1 and 4 patients were presented at the American Association for the Study of Liver Diseases (AASLD) congress, according to a Bristol-Myers Squibb media release.
    • 04 Apr 2012 Results will be presented at EASL-2012 according to a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top